Restless Legs Syndrome Treatment: Iron Repletion and Pharmacotherapy
Clinical Practice Update — Diagnosis, Iron Studies, and First-Line Drug Selection in Adults
This is an original clinical education article informed by current guidelines and evidence. See References below for source documents.
- Clinical Focus
- Diagnosis and first-line restless legs syndrome treatment in adults, including iron repletion
- Target Audience
- Family physicians, general practitioners, internists, nurse practitioners, pharmacists
- Setting
- Primary care and outpatient practice
- Source Evidence
- •AASM Clinical Practice Guideline on Treatment of RLS and PLMD (2025)
- •IRLSSG/MDS Consensus on Iron Treatment in RLS (Sleep Medicine, 2018)
- •AAN Practice Guideline on Treatment of RLS in Adults (Neurology, 2016)
- •European RLS Study Group Guidance on Augmentation (Sleep Medicine, 2016)
Key Clinical Takeaways
Effective restless legs syndrome treatment begins with a clinical diagnosis, an early check of iron stores, and a deliberate choice of first-line drug that minimises long-term harm. The points below distil the evidence into actionable rules you can apply in a routine primary care visit.
- 1Diagnose restless legs syndrome clinically using the five core features — no test confirms it, and routine sleep studies are not required.
- 2Check serum ferritin and transferrin saturation in every newly diagnosed patient before prescribing any drug.
- 3Replace iron when ferritin sits at or below 75 ng/mL with transferrin saturation under 45 percent — iron alone can resolve symptoms.
- 4Choose a gabapentinoid as the preferred first-line drug for most adults who need pharmacotherapy.
- 5Avoid starting dopamine agonists first-line because of the high long-term risk of augmentation.
- 6Review every patient’s medication list and stop or substitute agents that provoke symptoms, such as sedating antihistamines and certain antidepressants.
- 7Counsel patients on caffeine, alcohol, and sleep timing as part of every restless legs syndrome treatment plan.
- 8Recheck iron stores and symptom severity at follow-up, and treat worsening on a dopamine agonist as possible augmentation.
How to Confirm the Diagnosis Before Restless Legs Syndrome Treatment
Restless legs syndrome, also called Willis-Ekbom disease, is a clinical diagnosis. There is no confirmatory blood test or imaging study, so the entire decision rests on the history. Five features must all be present, and mimics must be reasonably excluded.
The hallmark is an urge to move the legs, almost always paired with an uncomfortable sensation, that appears or worsens during rest, eases with movement, and follows a clear evening or night-time rhythm. The fifth requirement is that another condition does not better explain the picture.
Diagnose restless legs syndrome on the five core clinical features alone. Reserve polysomnography for cases where another sleep disorder is suspected or the presentation is atypical.
Strong Rec High Evidence AASM 2025Evaluate for secondary causes at diagnosis, including iron deficiency, pregnancy, advanced kidney disease, and provoking medications. Treating the underlying contributor often improves symptoms without further drugs.
Strong Rec Moderate Evidence IRLSSG 2018Distinguish restless legs syndrome from nocturnal leg cramps, positional discomfort, peripheral neuropathy, and akathisia. Relief with movement and the evening rhythm are the most discriminating clues.
Moderate Rec Low Evidence AAN 2016Iron Repletion in Restless Legs Syndrome Treatment
Iron sits at the centre of restless legs syndrome treatment because brain iron availability, not just whole-body stores, drives symptoms. Many patients have normal haemoglobin yet insufficient iron for the central nervous system, which is why ferritin thresholds for treatment are set higher here than for anaemia.
Order ferritin together with transferrin saturation, and draw the sample fasting in the morning where possible, since ferritin rises with inflammation and can mislead. A single normal-looking ferritin does not rule out a meaningful iron deficit.
Measure serum ferritin and transferrin saturation in every newly diagnosed adult before starting drug therapy. Repeat the panel if symptoms escalate or fail to respond.
Strong Rec High Evidence IRLSSG 2018Start oral iron when ferritin is at or below 75 ng/mL and transferrin saturation is below 45 percent. A practical regimen is ferrous sulfate 325 mg with vitamin C on alternate days to improve absorption and tolerance.
Strong Rec Moderate Evidence IRLSSG 2018Consider intravenous iron infusion when oral iron is poorly tolerated, absorption is impaired, or symptoms are severe and a faster response is needed. Ferric carboxymaltose is a well-studied option in this setting.
Moderate Rec Moderate Evidence AASM 2025Recheck ferritin and transferrin saturation roughly 8 to 12 weeks after starting oral iron, and avoid further repletion once ferritin comfortably exceeds the treatment threshold to prevent iron overload.
Moderate Rec Low Evidence IRLSSG 2018First-Line Drugs for Restless Legs Syndrome Treatment
When symptoms are frequent or distressing despite iron repletion and lifestyle change, drug therapy is warranted. The major shift in recent guidance is the move away from dopamine agonists as the default and toward gabapentinoids for most adults, driven by the long-term burden of augmentation.
Gabapentinoids are particularly suited to patients with coexisting pain, anxiety, or insomnia, while dopamine agonists are now reserved for selected situations under closer supervision.
Prescribe a gabapentinoid — gabapentin enacarbil, gabapentin, or pregabalin — as the preferred first-line agent for most adults requiring pharmacotherapy. Start low and titrate to effect in the evening.
Strong Rec High Evidence AASM 2025Reduce the gabapentinoid dose in chronic kidney disease, since both gabapentin and pregabalin are renally cleared. Counsel patients about daytime sedation, dizziness, and the risk of falls in older adults.
Strong Rec Moderate Evidence AAN 2016Do not initiate a dopamine agonist as routine first-line therapy. Where one is genuinely needed, use the lowest effective dose and warn the patient about augmentation from the outset.
Against High Evidence AASM 2025 EU RLSSG 2016Review and rationalise medications that aggravate symptoms, including sedating antihistamines, dopamine-blocking antiemetics, and most serotonergic and noradrenergic antidepressants. Substitute where the original indication still stands.
Moderate Rec Low Evidence AASM 2025Counsel every patient on reducing evening caffeine and alcohol, maintaining regular sleep timing, and using movement or stretching when symptoms strike. These measures support pharmacotherapy rather than replace it in moderate-to-severe disease.
Moderate Rec Low Evidence AAN 2016First-Line Options: A Drug-by-Drug Guide
| Drug | Typical Evening Dose | Best Suited For | Practical Tips |
|---|---|---|---|
| Gabapentin enacarbil | 600 mg once daily, early evening | Moderate-to-severe RLS, predictable evening symptoms | More stable absorption than gabapentin; take with food. |
| Gabapentin | 100–300 mg, titrate upward | Coexisting pain or neuropathy; cost-sensitive patients | Absorption is dose-dependent; split larger doses. Reduce in renal impairment. |
| Pregabalin | 75–150 mg in the evening | Coexisting anxiety; need for simpler titration | Linear absorption; watch for weight gain and sedation. |
| Oral iron | Ferrous sulfate 325 mg, alternate days | Ferritin at or below 75 ng/mL, any severity | Pair with vitamin C; recheck stores at 8–12 weeks. |
| Dopamine agonist | Lowest effective dose only | Reserved, supervised use only | Not first-line. Counsel on augmentation before starting. |
Recognising and Avoiding Augmentation
Augmentation is the paradoxical worsening of symptoms caused by long-term dopaminergic therapy. It is the single most important reason these drugs have lost their first-line status, and recognising it early changes management entirely.
Suspect augmentation when symptoms start earlier in the day, spread to the arms or trunk, become more intense, or return faster after a dose. Increasing the dopamine agonist dose typically deepens the problem rather than relieving it.
Reassess for augmentation at every visit in any patient on a dopamine agonist. When it is identified, recheck iron stores and plan a transition by switching agents toward a gabapentinoid rather than escalating the dopaminergic dose.
Strong Rec Moderate Evidence EU RLSSG 2016Refer to a sleep or movement disorder specialist when symptoms are refractory, augmentation is severe, or an opioid is being considered. These decisions sit beyond routine first-line primary care management.
Moderate Rec Low Evidence AASM 2025Clinical Decision Pathway
A practical, question-based approach to the first visit and beyond. Work through the questions in sequence.
Monitoring and Follow-Up
Follow-up confirms response, catches augmentation early, and prevents iron overload. A simple severity question at each visit tracks progress well in primary care.
| Parameter | When to Check | What to Look For | Common Pitfalls |
|---|---|---|---|
| Ferritin and saturation | 8–12 weeks after starting iron | Rising ferritin above the treatment threshold | Rechecking too early; ferritin lags clinical change. |
| Symptom severity | Each follow-up visit | Frequency, timing, and impact on sleep | Relying on one global impression instead of specifics. |
| Augmentation features | Every visit on a dopamine agonist | Earlier onset, spread, or faster rebound | Treating worsening as undertreatment and raising the dose. |
| Sleep and daytime function | Each visit | Onset insomnia and any periodic limb movements at night | Overlooking sedation from the drug itself. |
Evidence in Context
What the evidence shows, where the major guidance converges, and where emphasis differs.
The Shift Away From Dopamine Agonists
Across recent guidance, the central change is that gabapentinoids are now favoured first-line for most adults, while dopamine agonists have moved to a reserved role. The driver is the cumulative, often irreversible burden of augmentation that emerges over years of dopaminergic use.
Where the Guidance Converges on Iron
There is broad agreement that iron status should be checked in every patient and that repletion can meaningfully reduce symptoms when the ferritin threshold for treatment is met. The exact numeric cut-offs vary slightly between sources, but the principle of treating below roughly 75 ng/mL is consistent.
Intravenous Iron: What the Trials Suggest
Randomised data support intravenous iron, particularly ferric carboxymaltose, as an effective option when oral iron fails or rapid benefit is needed. It is increasingly positioned as a legitimate early choice rather than a last resort in suitable patients.
The Role of Lifestyle and Provoking Drugs
Behavioural measures and removal of aggravating medications are universally endorsed as foundational, though the evidence base is modest. They rarely suffice alone in moderate-to-severe disease but consistently support the overall treatment plan.
References
- 1.Winkelman JW, Berkowski JA, DelRosso LM, et al. Treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2025;21(1):137–152. doi:10.5664/jcsm.11390
- 2.Allen RP, Picchietti DL, Aulé EJ, et al. Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children. Sleep Med. 2018;41:27–44. doi:10.1016/j.sleep.2017.11.1126
- 3.Winkelman JW, Armstrong MJ, Allen RP, et al. Practice guideline summary: Treatment of restless legs syndrome in adults. Neurology. 2016;87(24):2585–2593. doi:10.1212/WNL.0000000000003388
- 4.Garcia-Borreguero D, Silber MH, Winkelman JW, et al. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation. Sleep Med. 2016;21:1–11. doi:10.1016/j.sleep.2016.01.017
How to Read the Evidence Tags
Each recommendation carries two tags for recommendation strength and evidence quality — Medaptly’s own simplified interpretations, not any guideline body’s classification system.
Recommendation Strength
| Tag | What It Means |
|---|---|
| Strong Rec | High-quality evidence broadly supports this action. |
| Moderate Rec | The weight of evidence favours this action. |
| Conditional Rec | The benefit is less certain — individualise. |
| Against | Evidence shows no benefit or potential harm. |
Evidence Quality
| Tag | What It Means |
|---|---|
| High Evidence | Multiple well-designed RCTs or high-quality meta-analyses. |
| Moderate Evidence | Single RCT or large observational studies. |
| Low Evidence | Expert consensus or small studies. |